Thomas Desperito, MD
Urology · Wilmington, DENPI 1265536353
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,034 of the $7,138 with a category attached, or 84.5%. 35 manufacturers reported payments, led by Medtronic at 24.6% of the total. Among urology clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $33.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Neotract Inc.$1K
- Teleflex LLC$549
- Pfizer$392
- Sumitomo Pharma America, Inc.$362
- Bayer$249
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$501%
- Travel & lodging$1,01914%
- Food & beverage$6,03485%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 39 | $1,758 |
| Neotract Inc. | 5 | $1,386 |
| Teleflex LLC | 13 | $549 |
| Pfizer | 22 | $392 |
| Sumitomo Pharma America, Inc. | 24 | $362 |
| Bayer | 11 | $249 |
| Astellas Pharma US Inc | 15 | $246 |
| Axonics, Inc. | 4 | $218 |
| Procept Biorobotics Corporation | 4 | $171 |
| Ferring Pharmaceuticals Inc. | 3 | $166 |
| Novartis | 6 | $153 |
| Urogen Pharma, Inc. | 7 | $130 |
| Calyxo, Inc. | 1 | $129 |
| Tolmar, Inc. | 6 | $121 |
| Johnson & Johnson | 6 | $120 |
| Myriad Genetic Laboratories, Inc. | 7 | $109 |
| Myovant Sciences Inc. | 6 | $102 |
| AstraZeneca | 5 | $94 |
| AbbVie | 4 | $82 |
| 180 Medical, Inc. | 2 | $78 |
| Progenics Pharmaceuticals, Inc. | 2 | $65 |
| Valencia Technologies Corporation | 1 | $50 |
| Civco Medical Instruments | 1 | $50 |
| Photocure Inc | 2 | $46 |
| Urovant Sciences Inc | 2 | $43 |
| Telix Pharmaceuticals | 2 | $40 |
| Acerus Pharmaceuticals Corporation | 2 | $38 |
| Bluewind Medical | 1 | $33 |
| Dendreon Pharmaceuticals LLC | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Blue Earth Diagnostics | 1 | $23 |
| Accord Healthcare, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Olympus America Inc. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,331
- INTERSTIM$985
- UroLift System$142
- Axonics$139
- ADSTILADRIN$131
- CVAC Aspiration System$129
- XTANDI$119
- AquaBeam Robotic System$105
How this compares
$7,138 in reported general payments places this provider in the 90th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 71 | $989,690 |
| OrgovyxRelugolix | 101 | $400,134 |
| NubeqaDarolutamide | 17 | $264,024 |
| MyrbetriqMirabegron | 143 | $119,557 |
| GemtesaVibegron | 49 | $34,143 |
| Tamsulosin Hcl | 1,494 | $33,761 |
| Silodosin | 190 | $17,681 |
| Mirabegron ErMirabegron | 19 | $15,175 |
| Oxybutynin Chloride ErOxybutynin Chloride | 251 | $6,059 |
| Finasteride | 287 | $4,931 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 102 | $2,825 |
| Dutasteride | 49 | $2,395 |
| Cefpodoxime Proxetil | 126 | $1,867 |
| Cephalexin | 331 | $982 |
| Estradiol | 16 | $927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $246 | $1,109,247214 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $362 | $434,278150 claims |
| BayerNubeqa | $249 | $264,02417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 33 urology providers in Delaware.
Other urology in Wilmington
- Christopher MitchellWilmington$19K
- Michael LobisWilmington$8K
- Bruce BengeWilmington$5K
- Alice WangWilmington$4K
- Keara DecotiisWilmington$3K
- Mohamed IsmailWilmington$3K
- David CozzolinoWilmington$2K
- Mona YezdaniWilmington$2K
- Steven TerranovaWilmington$2K
- Andrew GlickWilmington$748
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.